Conclusion This study demonstrated changes in the actual number of semaglutide and dulaglutide prescriptions supplied for T2D treatment between January and September 2022, with reductions in the number of semaglutide and dulaglutide prescriptions supplied coinciding with the TGA announcements of shortages for semaglutide and dulaglutide in April and June 2022, respectively
Additionally, long-term demand is indirectly reinforced by initiatives that support domestic pharmaceutical manufacturing, preventive healthcare programs, and obesity awareness campaigns
However, the effects of Cbl on neurological disorders have been extensively studied
Research Citations Able, C., Liao, B., Saffati, G., et al
Retatrutide's known side effect profile from trials includes nausea, vomiting, diarrhoea, decreased appetite, and injection-site reactions effects consistent with other GLP-1-based therapies
Cardiovasc Toxicol 26 , 9 (2026)